Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma
暂无分享,去创建一个
[1] M. Terol,et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Licht,et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. , 2008, Blood.
[3] Barbara Kruk,et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma , 2008, Leukemia & lymphoma.
[4] D. Hose,et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14) , 2007, Bone Marrow Transplantation.
[5] H. Müller-Hermelink,et al. Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. , 2007, Blood.
[6] A. Rustgi,et al. Cyclin D1 Induction through IκB Kinase β/Nuclear Factor-κB Pathway Is Responsible for Arsenite-Induced Increased Cell Cycle G1-S Phase Transition in Human Keratinocytes , 2005 .
[7] S. Bicciato,et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[9] R. Mann,et al. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor , 2005, Development.
[10] Hong Chang,et al. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system , 2005, British journal of haematology.
[11] Y. Kaneko,et al. MYND‐less splice variants of AML1–MTG8 (RUNX1–CBFA2T1) are expressed in leukemia with t(8;21) , 2005, Genes, chromosomes & cancer.
[12] D. Christiansen,et al. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML , 2005, Leukemia.
[13] F. Zhan,et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray , 2004, Modern Pathology.
[14] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[15] J. Downing,et al. Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. , 2004, Blood.
[16] A. Takeshita,et al. Prognostic Significance of Surface Markers Expressed in Multiple Myeloma: CD56 and Other Antigens , 2004, Leukemia & lymphoma.
[17] H. Johnsen,et al. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities , 2003, British journal of haematology.
[18] M. Baccarani,et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. , 2003, Blood.
[19] N. Callander,et al. AML-1A and AML-1B regulation of MIP-1α expression in multiple myeloma , 2003 .
[20] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[21] H. Johnsen,et al. C-MAF Oncogene Dysregulation in Multiple Myeloma: Frequency and Biological Relevance , 2003, Leukemia & lymphoma.
[22] M. Lacy,et al. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. , 2002, Blood.
[23] R. Ohno,et al. Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma , 2002, British journal of haematology.
[24] H. Johnsen,et al. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance , 2002, British journal of haematology.
[25] A. Friedman,et al. AML1 stimulates G1 to S progression via its transactivation domain , 2002, Oncogene.
[26] S. Ely,et al. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. , 2002, The American journal of pathology.
[27] T. Rasmussen,et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma , 2002, British journal of haematology.
[28] H. Johnsen,et al. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma , 2001, European journal of haematology.
[29] P. L. Bergsagel,et al. Chromosome translocations in multiple myeloma , 2001, Oncogene.
[30] H. Johnsen,et al. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single‐cell and real‐time RT‐PCR assays , 1999, British journal of haematology.
[31] S. Barrans,et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.
[32] R. Bataille,et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma , 1998, Leukemia.
[33] G. Morgan,et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.
[34] G. Edelman,et al. A binding site for Pax proteins regulates expression of the gene for the neural cell adhesion molecule in the embryonic spinal cord. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] H. Asaoku,et al. Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.
[36] H. F. Barker,et al. Expression of adhesion molecules LFA‐3 and N‐CAM on normal and malignant human plasma cells , 1992, British journal of haematology.
[37] A T Look,et al. Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. , 1992, Genomics.
[38] P. Lacor,et al. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells , 1991, British journal of haematology.
[39] J. Drach,et al. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells , 1991, Clinical and experimental immunology.
[40] M. Mattei,et al. Localization of the human NCAM gene to band q23 of chromosome 11: the third gene coding for a cell interaction molecule mapped to the distal portion of the long arm of chromosome 11 , 1986, The Journal of cell biology.
[41] N. Callander,et al. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. , 2003, Blood.
[42] Stephen L. Nutt,et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 , 1999, Nature.
[43] B. Camp,et al. Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines , 1998, Leukemia.
[44] P. L. Bergsagel,et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.